Please use this identifier to cite or link to this item:
https://hdl.handle.net/1/1605
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chavada, Ruchir R. | - |
dc.contributor.other | Ghosh, N. | - |
dc.contributor.other | Maley, M. | - |
dc.contributor.other | Van Hal, S.J. | - |
dc.date.accessioned | 2019-08-28T03:51:45Z | en |
dc.date.available | 2019-08-28T03:51:45Z | en |
dc.date.issued | 2014-12 | - |
dc.identifier.citation | Volume 20, Issue 12: O1098 - 105 | en |
dc.identifier.issn | 1198-743x | en |
dc.identifier.uri | https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/1605 | en |
dc.description.abstract | Despite recent controversies about toxicity and reduced efficacy, vancomycin remains the current treatment of choice for methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia. The parameter associated with treatment success is the vancomycin 24-h area under concentration-time curve to MIC ratio (AUC0-24/MIC). We aimed to determine the utility of calculated AUCs and explore the optimal AUC0-24/MIC targets associated with treatment success. In this single-centre retrospective observational cohort study of 127 patients with MRSA bacteraemia, forty-five (35.4%) did not respond to vancomycin treatment. Patient characteristics were essentially the same between those who did not respond to vancomycin treatment and those with treatment success, with independent predictors of treatment failure being source of bacteraemia (odds ratio (OR), 4.29; 95% confidence interval (CI), 1.50-12.26; p 0.007) and not achieving an AUC0-24/MICBMD (using broth microdilution) target of >/=398 (OR, 11.4; 95% CI, 4.57-28.46; p< 0.001). Bacteraemic source-specific thresholds were observed with a higher AUC0-24/MICBMD target of 440 required for high-risk sources (e.g. infective endocarditis) compared with 330 for low-risk sources (line related bacteraemia). Overall treatment success in patients with MRSA bacteraemia was associated with a vancomycin AUC0-24/MICBMD target of >/=398, with source-specific targets observed. Future vancomycin practice guidelines will need to take into account MIC methodology, source of bacteraemia and patient populations prior to setting targets and monitoring recommendations. | en |
dc.description.sponsorship | Microbiology & Infectious Diseases | en |
dc.subject | Drug Therapy | en |
dc.subject | Microbiology | en |
dc.title | Impact of source of infection and vancomycin AUC0-24/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia | en |
dc.type | Journal Article | en |
dc.identifier.doi | 10.1111/1469-0691.12695 | en |
dc.description.pubmeduri | https://www.ncbi.nlm.nih.gov/pubmed/24890030 | en |
dc.identifier.journaltitle | Clinical Microbiology and Infection | en |
dc.originaltype | Text | en |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.openairetype | Journal Article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Pathology | - |
Appears in Collections: | Health Service Research |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.